Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Evaluation of a PCR method to determine the clinical significance of blood cultures with Staphylococcus epidermidis in patients with hematological malignancies.

Ahlstrand E, Bäckman A, Persson L, Mölling P, Tidefelt U, Söderquist B.

APMIS. 2014 Jun;122(6):539-44. doi: 10.1111/apm.12182. Epub 2013 Sep 30.

PMID:
24106819
2.

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO.

J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.

PMID:
22965953
3.

Adverse events during treatment of critical limb ischemia with autologous peripheral blood mononuclear cell implant.

Jonsson TB, Larzon T, Arfvidsson B, Tidefelt U, Axelsson CG, Jurstrand M, Norgren L.

Int Angiol. 2012 Feb;31(1):77-84.

PMID:
22330628
4.

Alteration of the colonization pattern of coagulase-negative staphylococci in patients undergoing treatment for hematological malignancy.

Ahlstrand E, Persson L, Tidefelt U, Söderquist B.

Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1679-87. doi: 10.1007/s10096-011-1493-6. Epub 2011 Nov 29.

PMID:
22124538
5.

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.

Deneberg S, Guardiola P, Lennartsson A, Qu Y, Gaidzik V, Blanchet O, Karimi M, Bengtzén S, Nahi H, Uggla B, Tidefelt U, Höglund M, Paul C, Ekwall K, Döhner K, Lehmann S.

Blood. 2011 Nov 17;118(20):5573-82. doi: 10.1182/blood-2011-01-332353. Epub 2011 Sep 29.

6.

Medical education in Sweden.

Lindgren S, Brännström T, Hanse E, Ledin T, Nilsson G, Sandler S, Tidefelt U, Donnér J.

Med Teach. 2011;33(10):798-803. doi: 10.3109/0142159X.2011.570816.

PMID:
21942478
7.

Glycopeptide resistance in coagulase-negative staphylococci isolated in blood cultures from patients with hematological malignancies during three decades.

Ahlstrand E, Svensson K, Persson L, Tidefelt U, Söderquist B.

Eur J Clin Microbiol Infect Dis. 2011 Nov;30(11):1349-54. doi: 10.1007/s10096-011-1228-8. Epub 2011 Apr 5.

PMID:
21744039
8.

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgård L, Derolf AR, Stockelberg D, Tidefelt U, Wahlin A, Wennström L, Höglund M, Juliusson G.

Leukemia. 2011 Jul;25(7):1128-34. doi: 10.1038/leu.2011.78. Epub 2011 Apr 19.

PMID:
21502956
9.

CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells.

Prenkert M, Uggla B, Tidefelt U, Strid H.

Anticancer Res. 2010 Oct;30(10):4157-61.

PMID:
21036735
10.

Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.

Tina E, Prenkert M, Höglund M, Paul C, Tidefelt U.

Oncol Rep. 2009 Dec;22(6):1527-31.

PMID:
19885609
11.

Rapid induction of P-glycoprotein mRNA and protein expression by cytarabine in HL-60 cells.

Prenkert M, Uggla B, Tina E, Tidefelt U, Strid H.

Anticancer Res. 2009 Oct;29(10):4071-6.

12.

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, Tidefelt U, Wahlin A, Höglund M.

Blood. 2009 Apr 30;113(18):4179-87. doi: 10.1182/blood-2008-07-172007. Epub 2008 Nov 13.

13.

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.

Löfgren C, Lehmann S, Jönsson-Videsäter K, Möllgård L, Linder O, Tidefelt U, Hassan M, Paul C.

Ther Drug Monit. 2007 Oct;29(5):626-31.

PMID:
17898654
14.

Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.

Uggla B, Tina E, Nahi H, Paul C, Höglund M, Sirsjö A, Tidefelt U.

Int J Oncol. 2007 Jul;31(1):153-60.

PMID:
17549416
15.
16.

Phenotypic and genotypic characterization of coagulase-negative staphylococci isolated in blood cultures from patients with haematological malignancies.

Persson L, Strid H, Tidefelt U, Söderquist B.

Eur J Clin Microbiol Infect Dis. 2006 May;25(5):299-309.

PMID:
16786376
17.

Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia.

Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U.

Eur J Haematol. 2005 Apr;74(4):297-303.

PMID:
15777341
18.

BCRP mRNA expression v. clinical outcome in 40 adult AML patients.

Uggla B, Ståhl E, Wågsäter D, Paul C, Karlsson MG, Sirsjö A, Tidefelt U.

Leuk Res. 2005 Feb;29(2):141-6.

PMID:
15607361
19.

Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia.

Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson LO, Tidefelt U.

Scand J Infect Dis. 2004;36(5):365-71.

PMID:
15287382
20.

Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.

Löfgren C, Paul C, Aström M, Hast R, Hedenius M, Lerner R, Liliemark J, Nilsson I, Rödjer S, Simonsson B, Stockelberg D, Tidefelt U, Björkholm M.

Br J Haematol. 2004 Feb;124(4):474-80.

PMID:
14984497

Supplemental Content

Loading ...
Support Center